30 closest matches · ranked by relevance
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Plasma Cell Myeloma · Multiple Myeloma
Primary: Percentage of Patients Achieving at Least 2 x 10^6 Cluster of Differentiation 34 (CD34) Cells Per Kg Recipient Body Weight on Day 1 of Apheresis — 98 percentage of…
Multiple Myeloma · Smoldering Multiple Myeloma · Monoclonal Gammopathy of Undetermined Significance
Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants
Multiple Myeloma
Primary: Immune Response — 7 Particpants
Plasma Cell Leukemia · Plasma Cell Myeloma · Plasmacytoma
Primary: Confirmed Response Rate — 0.06 proportion of patients
Multiple Myeloma
Primary: Percentage of Participants With 1-year Response Rate of CR/sCR — 52.9; 50.0 percentage of participants — p=0.3657
Multiple Myeloma
Primary: Number of Participants Achieving a Complete Response — 51 Participants
Lymphoma, Non-Hodgkin · Multiple Myeloma
Primary: Overall Participant Counts of Adverse Events (AEs) Up to Twelve Months Post Transplant — 7; 6; 1; 12 participants
Multiple Myeloma
Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…
Multiple Myeloma
Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Multiple Myeloma
Primary: Feasibility of Obtaining Baseline Clinical and PRO Data Capture From 200 Consented Patients. — 196 Participants
Smoldering Multiple Myeloma
Primary: 2 Year Progression Free Percent — 62.5 percentage of participants
Extramedullary Plasmacytoma · Isolated Plasmacytoma of Bone · Light Chain Deposition Disease
Primary: Median Progression Free Survival (mPFS) — 76.4 months
Plasma Cell Neoplasm
Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants
Multiple Myeloma
Primary: Therapeutic Efficacy — 1 Participants
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — 20 mg LBH589
Multiple Myeloma
Primary: Bone Formation Markers Measurement — 21.87; 23.2; 1.33; 28.75 U/L — p=0.002
Plasma Cell Disorder
Primary: Positive for Hepatitis B Surface Antigen — 4; 3 participants
Multiple Myeloma
Primary: Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein. — 2 Participants
Multiple Myeloma
Primary: Progression Free Survival — 16.7 Months
Multiple Myeloma
Primary: Number of Participants With Pulmonary Toxicity — 32 Participants
Multiple Myeloma · Plasma Cell Leukemia
Primary: Overall Survival (OS) — 40 months
Multiple Myeloma
Primary: Number of Multiple Myeloma (MM) Participants Categorized by Clinical Characteristics — 342; 366; 48; 36 Participants
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 7 participants
Multiple Myeloma · Auto Stem Cell Transplant
Primary: To Determine the Progression-free Survival of Patients With Multiple Myeloma Treated With Tandem Cycles of High-dose Melphalan Followed by High-dose Melphalan in…
Multiple Myeloma · Amyloidosis
Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants
Lymphoma, Non-Hodgkin · Multiple Myeloma
Primary: Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE) — 23; 26; 49; 8 participants
Multiple Myeloma
Primary: The Number of Patients That Achieve Complete Response — 7 Participants
Multiple Myeloma · Plasma Cell Myeloma
Primary: Overall Survival — 68 Months
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic and Organ Response — 11; 7; 18 participants